Edition:
India

BioXcel Therapeutics Inc (BTAI.OQ)

BTAI.OQ on NASDAQ Stock Exchange Capital Market

5.30USD
18 Oct 2019
Change (% chg)

$-0.50 (-8.62%)
Prev Close
$5.80
Open
$5.80
Day's High
$5.83
Day's Low
$5.22
Volume
12,028
Avg. Vol
18,617
52-wk High
$12.00
52-wk Low
$2.41

Latest Key Developments (Source: Significant Developments)

BioXcel Therapeutics Inc Affirms Expected Timeline Regarding Upcoming Milestones
Thursday, 10 Oct 2019 

Oct 10 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS INC - AFFIRMED ITS EXPECTED TIMELINE REGARDING UPCOMING MILESTONES.BIOXCEL THERAPEUTICS INC - CASH POSITION SUFFICIENT TO FUND DATA READOUTS FROM KEY CLINICAL TRIALS ON EXPECTED TIMELINE.  Full Article

BioXcel Therapeutics Announces Pricing Of Public Offering Of Common Stock
Thursday, 26 Sep 2019 

Sept 26 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 2.30 MILLION COMMON SHARES PRICED AT $8.25PER SHARE.  Full Article

BioXcel Therapeutics Reports Second Quarter 2019 Financial Results And Provides Business Update
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.BIOXCEL THERAPEUTICS INC - QTRLYLOSS PER SHARE $0.54.BIOXCEL THERAPEUTICS INC - WELL POSITIONED TO EXECUTE ON KEY MILESTONES WITH SUFFICIENT CASH TO FUND OPERATIONS THROUGH MID-2020.  Full Article

Bioxcel Therapeutics Reports Q1 Results
Tuesday, 7 May 2019 

May 7 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS REPORTS FIRST QUARTER 2019 RESULTS AND PROVIDES BUSINESS UPDATE.QTRLY LOSS PER SHARE $0.46.Q1 EARNINGS PER SHARE VIEW $-0.55 -- REFINITIV IBES DATA.  Full Article

BioXcel Therapeutics Files Clinical Trial Application for the Development of BXCL701 and Pembrolizumab in Neuroendocrine Prostate Cancer
Monday, 25 Mar 2019 

March 25 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS FILES CLINICAL TRIAL APPLICATION FOR THE DEVELOPMENT OF BXCL701 AND PEMBROLIZUMAB IN NEUROENDOCRINE PROSTATE CANCER (TNEPC).BIOXCEL THERAPEUTICS -FILED CLINICAL TRIAL APPLICATION WITH U.K. HEALTH AUTHORITIES FOR BXCL701 IN COMBINATION WITH PEMBROLIZUMAB (KEYTRUDA), IN TNEPC.BIOXCEL THERAPEUTICS - PREPARING TO FILE IND APPLICATION WITH FDA FOR CLINICAL TRIAL EVALUATING TRIPLE COMBINATION OF BXCL701, NKTR-214 & AVELUMAB.  Full Article

Bioxcel Therapeutics Net Loss Of $7.1 Mln For Q4 Of 2018
Thursday, 7 Mar 2019 

March 7 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 QUARTERLY RESULTS AND PROVIDES BUSINESS UPDATE.BIOXCEL THERAPEUTICS INC - BXCL501 PHARMACOKINETIC (BIOAVAILABILITY) AND SAFETY STUDY ON TRACK TO READ OUT IN Q2 2019.BIOXCEL THERAPEUTICS INC - NET LOSS OF $7.1 MILLION FOR Q4 OF 2018, COMPARED TO A NET LOSS OF $2.5 MILLION FOR SAME PERIOD IN 2017.  Full Article

Bioxcel Reports Positive Proof-Of-Concept Data For Treatment Of Agitation In Alzheimer's Patients
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS REPORTS POSITIVE HUMAN PROOF-OF-CONCEPT DATA FOR ACUTE TREATMENT OF AGITATION IN PATIENTS WITH ALZHEIMER’S DISEASE.BIOXCEL THERAPEUTICS INC - PRIMARY ENDPOINT (SAFETY AND TOLERABILITY) MET, WITH CLINICAL BENEFIT OBSERVED IN 7 OF 10 PATIENTS.BIOXCEL - PROOF-OF-CONCEPT ESTABLISHED IN AGITATED PATIENTS ACROSS MULTIPLE DISORDERS INCLUDING ALZHEIMER'S DISEASE, SCHIZOPHRENIA, AND DELIRIUM.BIOXCEL THERAPEUTICS INC - DRUG WAS WELL TOLERATED WITHOUT ANY CLINICALLY SIGNIFICANT ADVERSE EVENTS..BIOXCEL THERAPEUTICS INC - EXPECTS TO REPORT TOP-LINE DATA FROM BXCL 501 PROGRAM IN FIRST HALF OF 2019..  Full Article

BioXcel Therapeutics Announces FDA Acceptance Of IND For Lead Cancer Drug
Monday, 5 Nov 2018 

Nov 5 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF IND FOR LEAD IMMUNO-ONCOLOGY CANDIDATE, BXCL701, IN TREATMENT EMERGENT NEUROENDOCRINE PROSTATE CANCER.BIOXCEL THERAPEUTICS INC - FIRST-IN-HUMAN PHASE 1B / 2 COMBINATION TRIAL OF BXCL701 AND PEMBROLIZUMAB (KEYTRUDA®) EXPECTED TO INITIATE IN 4Q 2018.BIOXCEL THERAPEUTICS INC - EFFICACY STUDY WITH OBJECTIVE RESPONSE RATE ENDPOINT TO ENROLL UP TO 40 PATIENTS AT MULTIPLE CLINICAL SITES.  Full Article

Artemis Investment Management LLP Reports 7.74 pct Passive Stake In Bioxcel Therapeutics Inc As Of March 12
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Bioxcel Therapeutics Inc ::ARTEMIS INVESTMENT MANAGEMENT LLP REPORTS 7.74 PERCENT PASSIVE STAKE IN BIOXCEL THERAPEUTICS INC AS OF MARCH 12, 2018 - SEC FILING‍​.  Full Article

Bioxcel Therapeutics Sees IPO Of 5.0 Mln Shares Of Common Stock Priced Between $11.00 And $13.00 Per Share
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Bioxcel Therapeutics Inc ::BIOXCEL THERAPEUTICS INC SEES IPO OF 5.0 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $11.00 AND $13.00 PER SHARE - SEC FILING.BIOXCEL THERAPEUTICS INC SAYS INTENDS TO USE ABOUT $25 MILLION OF IPO NET PROCEEDS TO FUND BXCL501 THROUGH PHASE 2 CLINICAL DEVELOPMENT.BIOXCEL THERAPEUTICS INC SAYS INTENDS TO USE ABOUT $17 MILLION OF IPO NET PROCEEDS TO FUND BXCL701 THROUGH PHASE 2 CLINICAL DEVELOPMENT.  Full Article